Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer

Results of an exploratory analysis

S. Glück, C. Russell, J. O'Shaughnessy, E. F. McKenna, S. Hu, D. Odom, J. L. Blum

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus docetaxel (D) or D alone in a randomised phase III trial. Data were retrospectively analysed from patients whose disease had recurred following (neo)adjuvant anthracyclines. ER status was identified in 356/506 patients. In patients with ER-positive tumours, median overall survival from enrolment was 17.7 months with CD versus 12.5 months with D (hazard ratio [HR] 0.65, 95% confidence interval [CI]: 0.47-0.89; P=0.007) and median time to progression (TTP) was 6.8 and 5.4 months, respectively (HR 0.62, 95% CI: 0.46-0.84; P=0.002). For patients with ER-negative tumours, significantly longer TTP was seen with CD (5.2 versus 3.5 months; HR 0.73, 95% CI: 0.53-0.98; P=0.038). Whether there is an additional C to D treatment benefit in ER-positive versus ER-negative MBC requires further evaluation.

Original languageEnglish
Pages (from-to)1087-1093
Number of pages7
JournalBreast
Volume22
Issue number6
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

docetaxel
Breast Neoplasms
Confidence Intervals
Women's Rights
Anthracyclines
Therapeutics
Estrogen Receptors
Neoplasms
Survival
Capecitabine

Keywords

  • Capecitabine
  • Docetaxel
  • Exploratory analysis
  • Hormone receptor status
  • Metastatic breast cancer
  • Survival

ASJC Scopus subject areas

  • Surgery

Cite this

Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer : Results of an exploratory analysis. / Glück, S.; Russell, C.; O'Shaughnessy, J.; McKenna, E. F.; Hu, S.; Odom, D.; Blum, J. L.

In: Breast, Vol. 22, No. 6, 01.12.2013, p. 1087-1093.

Research output: Contribution to journalArticle

Glück, S. ; Russell, C. ; O'Shaughnessy, J. ; McKenna, E. F. ; Hu, S. ; Odom, D. ; Blum, J. L. / Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer : Results of an exploratory analysis. In: Breast. 2013 ; Vol. 22, No. 6. pp. 1087-1093.
@article{b1d092ffe5b641fe933a4e933c74b90b,
title = "Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer: Results of an exploratory analysis",
abstract = "We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus docetaxel (D) or D alone in a randomised phase III trial. Data were retrospectively analysed from patients whose disease had recurred following (neo)adjuvant anthracyclines. ER status was identified in 356/506 patients. In patients with ER-positive tumours, median overall survival from enrolment was 17.7 months with CD versus 12.5 months with D (hazard ratio [HR] 0.65, 95{\%} confidence interval [CI]: 0.47-0.89; P=0.007) and median time to progression (TTP) was 6.8 and 5.4 months, respectively (HR 0.62, 95{\%} CI: 0.46-0.84; P=0.002). For patients with ER-negative tumours, significantly longer TTP was seen with CD (5.2 versus 3.5 months; HR 0.73, 95{\%} CI: 0.53-0.98; P=0.038). Whether there is an additional C to D treatment benefit in ER-positive versus ER-negative MBC requires further evaluation.",
keywords = "Capecitabine, Docetaxel, Exploratory analysis, Hormone receptor status, Metastatic breast cancer, Survival",
author = "S. Gl{\"u}ck and C. Russell and J. O'Shaughnessy and McKenna, {E. F.} and S. Hu and D. Odom and Blum, {J. L.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1016/j.breast.2013.08.016",
language = "English",
volume = "22",
pages = "1087--1093",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer

T2 - Results of an exploratory analysis

AU - Glück, S.

AU - Russell, C.

AU - O'Shaughnessy, J.

AU - McKenna, E. F.

AU - Hu, S.

AU - Odom, D.

AU - Blum, J. L.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus docetaxel (D) or D alone in a randomised phase III trial. Data were retrospectively analysed from patients whose disease had recurred following (neo)adjuvant anthracyclines. ER status was identified in 356/506 patients. In patients with ER-positive tumours, median overall survival from enrolment was 17.7 months with CD versus 12.5 months with D (hazard ratio [HR] 0.65, 95% confidence interval [CI]: 0.47-0.89; P=0.007) and median time to progression (TTP) was 6.8 and 5.4 months, respectively (HR 0.62, 95% CI: 0.46-0.84; P=0.002). For patients with ER-negative tumours, significantly longer TTP was seen with CD (5.2 versus 3.5 months; HR 0.73, 95% CI: 0.53-0.98; P=0.038). Whether there is an additional C to D treatment benefit in ER-positive versus ER-negative MBC requires further evaluation.

AB - We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus docetaxel (D) or D alone in a randomised phase III trial. Data were retrospectively analysed from patients whose disease had recurred following (neo)adjuvant anthracyclines. ER status was identified in 356/506 patients. In patients with ER-positive tumours, median overall survival from enrolment was 17.7 months with CD versus 12.5 months with D (hazard ratio [HR] 0.65, 95% confidence interval [CI]: 0.47-0.89; P=0.007) and median time to progression (TTP) was 6.8 and 5.4 months, respectively (HR 0.62, 95% CI: 0.46-0.84; P=0.002). For patients with ER-negative tumours, significantly longer TTP was seen with CD (5.2 versus 3.5 months; HR 0.73, 95% CI: 0.53-0.98; P=0.038). Whether there is an additional C to D treatment benefit in ER-positive versus ER-negative MBC requires further evaluation.

KW - Capecitabine

KW - Docetaxel

KW - Exploratory analysis

KW - Hormone receptor status

KW - Metastatic breast cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84887135458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887135458&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2013.08.016

DO - 10.1016/j.breast.2013.08.016

M3 - Article

VL - 22

SP - 1087

EP - 1093

JO - Breast

JF - Breast

SN - 0960-9776

IS - 6

ER -